Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Pharmacoeconomic Report. 2014 Authors' conclusions At the submitted daily cost of $v.vvvv, the cost of saxagliptin is less than that of sitagliptin ($2.95; 100 mg) but is higher than or equal to that of linagliptin ($2.25 to $2.55; 5 mg). Due to variation in reimbursement prices for DPP-4 across the country, the price of saxagliptin would need to be reduced by at least vvvvvv% (to $2.25) to avoid incurring additional costs to plans that cover linagliptin. If saxagliptin were to replace sitagliptin as the most widely used DPP-4 drug, this would generate substantial cost savings for public plans. Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitorss Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000844 Date abstract record published 17/07/2014 |